These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32920632)

  • 1. The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs.
    Cummings J
    J Prev Alzheimers Dis; 2020; 7(4):288-290. PubMed ID: 32920632
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research.
    Porsteinsson AP; Clark ED
    J Prev Alzheimers Dis; 2020; 7(4):206-207. PubMed ID: 32920620
    [No Abstract]   [Full Text] [Related]  

  • 3. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.
    Aisen PS; Sperling RA; Cummings J; Donohue MC; Langford O; Jimenez-Maggiora GA; Rissman RA; Rafii MS; Walter S; Clanton T; Raman R
    J Prev Alzheimers Dis; 2020; 7(4):208-212. PubMed ID: 32920621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
    Reiman EM; Langbaum JB; Tariot PN; Lopera F; Bateman RJ; Morris JC; Sperling RA; Aisen PS; Roses AD; Welsh-Bohmer KA; Carrillo MC; Weninger S
    Nat Rev Neurol; 2016 Jan; 12(1):56-61. PubMed ID: 26416539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial dysfunction: A potential target for Alzheimer's disease intervention and treatment.
    Ke J; Tian Q; Xu Q; Fu Z; Fu Q
    Drug Discov Today; 2021 Aug; 26(8):1991-2002. PubMed ID: 33962036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.
    Hung A; Schneider M; Lopez MH; McClellan M
    J Manag Care Spec Pharm; 2020 Jul; 26(7):888-900. PubMed ID: 32584672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stop Alzheimer's before it starts.
    McDade E; Bateman RJ
    Nature; 2017 Jul; 547(7662):153-155. PubMed ID: 28703214
    [No Abstract]   [Full Text] [Related]  

  • 8. Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease.
    Hendrix SB; Soininen H; van Hees AMJ; Ellison N; Visser PJ; Solomon A; Attali A; Blennow K; Kivipelto M; Hartmann T
    J Prev Alzheimers Dis; 2019; 6(4):232-236. PubMed ID: 31686094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
    Aisen PS; Raman R
    J Prev Alzheimers Dis; 2020; 7(3):195-196. PubMed ID: 32463073
    [No Abstract]   [Full Text] [Related]  

  • 11. A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group.
    O'Gorman C; Khoury R; Anderson A; Carter M; DiCesare F; Dubé S; Ereshefsky L; Grossberg G; Hefting N; Khan S; Lind S; Moebius H; Shiovitz T; Rosenberg P
    J Prev Alzheimers Dis; 2020; 7(4):274-282. PubMed ID: 32920630
    [No Abstract]   [Full Text] [Related]  

  • 12. Be open about drug failures to speed up research.
    Alteri E; Guizzaro L
    Nature; 2018 Nov; 563(7731):317-319. PubMed ID: 30425369
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: Accelerating Preclinical Alzheimer's Clinical Trials through a Trial-Ready Cohort with Diverse Representation.
    Lee AKW; Correia S; Salloway SP
    J Prev Alzheimers Dis; 2020; 7(4):204-205. PubMed ID: 32920619
    [No Abstract]   [Full Text] [Related]  

  • 14. New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.
    Wei H
    Curr Alzheimer Res; 2020; 17(4):311-312. PubMed ID: 32623998
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's disease: future drug development and the blood-brain barrier.
    Pardridge WM
    Expert Opin Investig Drugs; 2019 Jul; 28(7):569-572. PubMed ID: 31155971
    [No Abstract]   [Full Text] [Related]  

  • 16. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
    Camins A; Ettcheto M; Busquets O; Manzine PR; Castro-Torres RD; Beas-Zarate C; Verdaguer E; Sureda FX; Bulló M; Olloquequi J; Auladell C; Folch J
    Expert Opin Investig Drugs; 2019 Jan; 28(1):93-97. PubMed ID: 30480461
    [No Abstract]   [Full Text] [Related]  

  • 17. Preclinical Alzheimer's Disease: Implications for Refinement of the Concept.
    Vos SJB; Visser PJ
    J Alzheimers Dis; 2018; 64(s1):S213-S227. PubMed ID: 29865060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
    Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
    Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do preclinical Alzheimer's disease criteria work?
    Petersen RC
    Lancet Neurol; 2013 Oct; 12(10):933-5. PubMed ID: 24012373
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical Alzheimer's disease criteria.
    Fagan AM; Vos SJ
    Lancet Neurol; 2013 Dec; 12(12):1134. PubMed ID: 24025450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.